Ambrx Biopharma Inc.
NYSE:AMAM
28 (USD) • At close March 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Operating Activities: | ||||
| Net Income
| -77.996 | -68.288 | -17.839 | -22.313 |
| Depreciation & Amortization
| 1.803 | 2.154 | 1.943 | 2.053 |
| Deferred Income Tax
| 0 | 0.513 | 0 | 0.011 |
| Stock Based Compensation
| 6.253 | 11.856 | 1.217 | 1.831 |
| Change In Working Capital
| -10.621 | 3.64 | -7.375 | 14.176 |
| Accounts Receivables
| 0.863 | -0.811 | 0.415 | -0.762 |
| Inventory
| 0 | 6.131 | -3.263 | 0.151 |
| Accounts Payables
| -1.829 | 2.403 | -3.247 | 3.776 |
| Other Working Capital
| -9.655 | -4.083 | -1.28 | 11.011 |
| Other Non Cash Items
| 11.886 | 5.485 | 1.478 | 1.477 |
| Operating Cash Flow
| -68.675 | -44.64 | -20.576 | -2.765 |
| Investing Activities: | ||||
| Investments In Property Plant And Equipment
| -1.054 | -3.206 | -0.252 | -0.048 |
| Acquisitions Net
| 45.664 | 0 | 0 | 0 |
| Purchases Of Investments
| -84.852 | 0 | 0 | 0 |
| Sales Maturities Of Investments
| 39.188 | 0 | 0 | 0 |
| Other Investing Activites
| -45.664 | 0 | 0 | 0 |
| Investing Cash Flow
| -46.718 | -3.206 | -0.252 | -0.048 |
| Financing Activities: | ||||
| Debt Repayment
| 0 | 0 | -1.339 | 0 |
| Common Stock Issued
| 0 | 148.732 | 0 | 0 |
| Common Stock Repurchased
| 0 | 0 | 0 | 0 |
| Dividends Paid
| 0 | 0 | 0 | 0 |
| Other Financing Activities
| 0.928 | -21.305 | 97.017 | 0 |
| Financing Cash Flow
| 0.928 | 127.427 | 95.678 | 0 |
| Other Information: | ||||
| Effect Of Forex Changes On Cash
| 0 | 0.047 | 0.165 | -0.038 |
| Net Change In Cash
| -114.465 | 79.628 | 75.015 | -2.851 |
| Cash At End Of Period
| 56.441 | 170.906 | 91.278 | 16.263 |